专利检索 ap:("Eiger Biopharmaceuticals, Inc." OR "The Board of Trustees of the Leland Stanford Junior University") AND inv:"Debra ODINK" 第 1 页

1.

发明公开
Buffered Formulations Of Exendin (9-39) 审中-公开

公开(公告)号：US20240042035A1

公开(公告)日：2024-02-08

申请号：US18339305

申请日：2023-06-22

申请人： Eiger Biopharmaceuticals, Inc. , The Board of Trustees of the Leland Stanford Junior University

发明人： Xiaofeng XIONG , Debra ODINK , Colleen M. CRAIG , Christine M.N. Smith , Tracey L. McLaughlin

IPC分类号： A61K47/12 , A61P3/10 , A61K9/00 , A61K38/26 , A61K47/26

CPC分类号： A61K47/12 , A61P3/10 , A61K9/0019 , A61K38/26 , A61K47/26

摘要： Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.